Hepta | Liquid biopsy, built for chronic disease

Tissue-level biology
from a tube of blood.

Hepta is decoding tissue-level biology from blood, starting with metabolic dysfunction-associated steatohepatitis (MASH).
LiquidTransformer, our liquid biopsy-native AI platform, reads epigenetic patterns in cell-free DNA — built from the ground up for the molecular signal regime of chronic disease.

Foundation

LiquidTransformer — the first liquid biopsy-native AI platform.

Designed to capture the faint signals from cell-free DNA fragments in chronic disease, our patented transformer-based model uses the attention mechanism to determine fragment significance at a single-molecule level. Unlike traditional liquid biopsy methods, LiquidTransformer captures the molecular signal in blood that reflects the molecular state of the tissue. Validated in our MASH Atlas — a paired plasma–tissue multiomics study.

AASLD 2025 oral podium presentation · manuscript in submission

Diagnostic

Identify the patients eligible for therapy.

A blood-based test that identifies patients with clinically significant MASH fibrosis (F2-F3), the population eligible for current and emerging therapies. Validated across multiple biopsy-confirmed cohorts and outperforming currently recommended guideline tests.

EASL 2026 oral podium presentation · manuscript in preparation

Therapy response

Match biology to therapy. Monitor response.

Differentially methylated pathways distinguish MASH patients who respond to GLP-1 therapy from those who do not, before treatment begins. The same architecture supports response monitoring and mechanism-of-action insight across the broader MOA landscape.

DDW 2026 oral podium presentation · manuscript in preparation

Tissue-level biology
from a tube of blood.

MASH is treatable,
if we find it in time.

A common chronic disease, largely invisible in routine practice.

Current diagnostic pathways do not scale.

A simple, reliable blood test for tissue-level insight.

One blood test to answer biological questions that today require biopsy.

LiquidTransformer — the first liquid biopsy-native AI platform.

Identify the patients eligible for therapy.

Match biology to therapy. Monitor response.

Peer-reviewed forums where our science is being presented.

Built by veterans
of liquid biopsy and MASH.

Hamed Amini, PhD

Soheil Damangir, PhD

Rohit Loomba, MD MHSc

World-leading experts advising
and collaborating with Hepta.

Anna Mae Diehl, MD

Brent Tetri, MD

Scott Friedman, MD

Manal Abdelmalek, MD

Jörn Schattenberg, MD PhD

Arun Sanyal, MD

Mary Rinella, MD

Quentin Anstee, PhD FRCP

Vlad Ratziu, MD

Nizar Zein, MD

Mazen Noureddin, MD

Naim Alkhouri, MD

Bilal Hameed, MD

Stefano Romeo, MD PhD

Vincent Wong, MD

Hepta in public.

Get in touch.

Tissue-level biologyfrom a tube of blood.

MASH is treatable,if we find it in time.

A common chronic disease, largely invisible in routine practice.

Current diagnostic pathways do not scale.

A simple, reliable blood test for tissue-level insight.

One blood test to answer biological questions that today require biopsy.

LiquidTransformer — the first liquid biopsy-native AI platform.

Identify the patients eligible for therapy.

Match biology to therapy. Monitor response.

Peer-reviewed forums where our science is being presented.

Built by veteransof liquid biopsy and MASH.

Hamed Amini, PhD

Soheil Damangir, PhD

Rohit Loomba, MD MHSc

World-leading experts advisingand collaborating with Hepta.

Anna Mae Diehl, MD

Brent Tetri, MD

Scott Friedman, MD

Manal Abdelmalek, MD

Jörn Schattenberg, MD PhD

Arun Sanyal, MD

Mary Rinella, MD

Quentin Anstee, PhD FRCP

Vlad Ratziu, MD

Nizar Zein, MD

Mazen Noureddin, MD

Naim Alkhouri, MD

Bilal Hameed, MD

Stefano Romeo, MD PhD

Vincent Wong, MD

Hepta in public.

Get in touch.

Tissue-level biology
from a tube of blood.

MASH is treatable,
if we find it in time.

Built by veterans
of liquid biopsy and MASH.

World-leading experts advising
and collaborating with Hepta.